Evidence map›Paper›PMID 25256255›Full record

ArticleThorax2015

Children and young adults with CF in the USA have better lung function compared with the UK.

Christopher H Goss, Stephanie J MacNeill, Hebe B Quinton, Bruce C Marshall, Alexander Elbert, Emily A Knapp, Kristofer Petren, Elaine Gunn, Joanne Osmond, Diana Bilton

Open access · bronzeAbstract readComparative Study
In one paragraph

Article in Thorax, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 57 citations in OpenAlex.

  1. Guideline
  2. Article
  3. Article
  4. Quality of anthropometric data measured in children and adolescents with cystic fibrosis: a scoping review.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo · 2023
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Pragmatic criteria to define chronic pseudomonas aeruginosa infection among adults with cystic fibrosis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Article
  11. Article
  12. Article
  13. Data Resource Profile: The UK Cystic Fibrosis Registry.International journal of epidemiology · 2018
    Article
  14. Article
  15. Review
  16. Does current reporting of lung function by the UK cystic fibrosis registry allow a fair comparison of adult centres?Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2017
    Article
  17. Article
  18. Article
  19. Cystic fibrosis.Nature reviews. Disease primers · 2015
    Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 2 countries.

Christopher H GossDepartment of Medicine, University of Washington, Seattle, Washington, USA.
Stephanie J MacNeillDepartment of Occupational and Environmental Medicine, Imperial College London, London, UK.
Hebe B QuintonValue Reporting and Analytics, Dartmouth-Hitchcock Medical Center, Hanover, New Hampshire, USA.
Bruce C MarshallCystic Fibrosis Foundation, Bethesda, Maryland, USA.
Alexander ElbertCystic Fibrosis Foundation, Bethesda, Maryland, USA.
Emily A KnappCystic Fibrosis Foundation, Bethesda, Maryland, USA.
Kristofer PetrenCystic Fibrosis Foundation, Bethesda, Maryland, USA.
Elaine GunnUK Cystic Fibrosis Trust, London, UK.
Joanne OsmondUK Cystic Fibrosis Trust, London, UK.
Diana BiltonDepartment of Respiratory Medicine, Royal Brompton Hospital, London, UK.
Cystic Fibrosis Foundation · USCystic Fibrosis Trust · GBDartmouth–Hitchcock Medical Center · USImperial College London · GBRoyal Brompton Hospital · GBUniversity of Washington · US

Funding

Translational Research Center to Expedite Novel Therapies in Cystic FibrosisP30DK089507 · NIDDK · SEATTLE CHILDREN'S HOSPITAL · PI Christopher Hooper Goss, Lucas R Hoffman · 2010 to 2026
$21.4M
Proof of Principle Evaluation of IV Gallium Nitrate in Patients with CFUM1HL119073 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, SINGH, PRADEEP K · 2013 to 2017
$4.8M
Early Intervention in Pulmonary Exacerbation in CFR01HL103965 · NHLBI · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER, LECHTZIN, NOAH · 2010 to 2014
$3.8M
Investigating treatment resistance mechanisms in chronic bacterial infectionsR01AI101307 · NIAID · UNIVERSITY OF WASHINGTON · PI BRUCE, JAMES EDWARD, MANOIL, COLIN · 2012 to 2016
$2.9M
Regulation of host inflammatory responses and outcome in melioidosis by TLR5R01HL113382 · NHLBI · UNIVERSITY OF WASHINGTON · PI WEST, TIMOTHY EOIN · 2012 to 2016
$2.6M
Phase 2 Study of Intravenous Gallium Nitrate in the Treatment of Cystic FibrosisR01FD003704 · FDA · UNIVERSITY OF WASHINGTON · PI GOSS, CHRISTOPHER HOOPER · 2009 to 2018
$2.0M
FDA HHS R01 FD003704FDA HHS R01FD003704Medical Research Council G0802448NHLBI NIH HHS R01 HL103965NHLBI NIH HHS R01HL103965NHLBI NIH HHS R01 HL113382NHLBI NIH HHS R01HL113382NHLBI NIH HHS U M1HL119073NIAID NIH HHS R01 AI101307NIAID NIH HHS R01AI101307NIDDK NIH HHS P30 DK089507NIDDK NIH HHS P30DK089507
6 · The paper itself

Abstract

backgroundPeople with cystic fibrosis (CF) are managed differently in the USA and UK providing an opportunity to learn from differences in practice patterns.

objectivesTo compare cross-sectional demographics, practice patterns and clinical outcomes between US and UK CF patients.

methodsThis was a cross-sectional study using 2010 data from patients in the US Cystic Fibrosis Foundation and the UK Cystic Fibrosis patient registries. The a priori outcome measures of interest were lung function and nutritional status. Descriptive statistics and two sample comparisons were performed. Stratification and multivariable linear regression were used to adjust for confounding.

resultsThe study cohort included 13 777 children and 11 058 adults from the USA and 3968 children and 3965 adults from the UK. In children, mean body mass index centiles were similar. Lung function (FEV1 and FVC% predicted) was significantly higher in US patients ages 6-25 years of age. In a regression model adjusted for only age, FEV1% predicted was on average 3.31% of predicted (95% CI 2.65 to 3.96) higher in the USA compared with the UK. When adjusted for age, age at diagnosis, gender, pancreatic insufficiency and genotype, FEV1% predicted was on average 3.03% of predicted (95% CI 2.37 to 3.69) higher in the USA compared with the UK These differences persisted despite adjustment for possible confounders. Hypertonic saline and dornase alfa were much more commonly prescribed in US children.

conclusionsChildren and young adults with CF have better lung function in the USA compared with the UK despite similar nutritional status.

Indexed as

Practice Patterns, Physicians'AdolescentAdultAge FactorsAnti-Bacterial AgentsBody Mass IndexChildCross-Sectional StudiesCystic FibrosisDeoxyribonuclease IFemaleForced Expiratory VolumeHumansMaleMiddle AgedNutritional StatusAnti-Bacterial AgentsDeoxyribonuclease Idornase alfaRecombinant ProteinsSaline Solution, HypertonicClinical EpidemiologyCystic FibrosisPaediatric Lung Disaese

Identifiers

PMID25256255
PMCPMC4838510
OpenAlexW2110687313

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.